Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis

Abstract

SH was well tolerated and tended to show a faster efficacy than did the CMC-based formulation in patients with moderate dry eye and superficial keratitis. SH could therefore advantageously be prescribed from the early stages of dry eye disease. This study also showed that flow cytometry in impression cytology specimens is a reliable tool for exploring the ocular surface at the epithelial level and that CD44, in addition to HLA DR, could be an interesting endpoint for future trials in dry eye syndrome with products based on SH.

Effect of Hypotonic 0.18% Sodium Hyaluronate Eyedrops on Inflammation of the Ocular Surface in Experimental Dry Eye

“…According to a recent study, the use of hypotonic SH eyedrops in patients with moderate dry eye was beneficial in improving symptoms and signs of dry eye and decreasing the number of CD44 + cells on the conjunctiva. 37 They demonstrated that, after hyaluron bound with CD44 on the cell surface, the CD44-hyaluron complex was internalized and degraded within lysosomes, which was evidenced by increased CD63. 37 We also found that the hypotonic 0.18% SH group had the lowest number of CD44 + cells among the groups.…”

“…[33][34][35] In addition, in vivo corneal abrasion models have shown the dosedependent ability of hyaluronate to reduce wound size. 36 Clinically, Brignole et al 37 demonstrated that hypotonic 0.18% SH tended to show faster recovery in superficial keratitis and more improvement of subjective symptoms than 0.5% CMC eyedrops in patients with moderate dry eye. In the present study, we demonstrated that 0.18% SH eyedrops showed better results in corneal irregularity and staining scores compared with 0.5% CMC and 0.1% SH eyedrops.…”

Sodium Hyaluronate Decreases Ocular Surface Toxicity Induced by Benzalkonium Chloride–Preserved Latanoprost: An In Vivo Study

“…Besides the antioxidative nature and possible cooperation with latanoprost, SH may decrease expression of apoptosis-related inflammatory markers, Fas, APO2.7, HLA-DR, and CD40 through CD44 mediation, just like in treatment of moderate dry eye syndrome and superficial keratitis. 41 A limitation of this study is lack of detecting the expression of inflammatory cytokines. Our further understanding of the mechanism was limited due to the poor availability of antibodies against rabbit proteins.…”

Controlled Release of High Molecular Weight Hyaluronic Acid from Molecularly Imprinted Hydrogel Contact Lenses

“…HA has been used as a topically delivered artificial tear solution for over 20 years (12), and it has a proven track record for the treatment of ocular discomfort and dry eye syndrome (13)(14)(15). Two HA eye drop formulations that are currently on the market are VISMED® and AQuify™.…”